Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]Mufemilast in Healthy Male Adults
NCT05468645Phase 1Completed
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mufemilast in psoriasis and Behcet's disease (BD), sponsored by Hemay Pharmaceutical Technology. Primary endpoint: Pharmacokinetic (PK) profile of Hemay005. Started Jul 2022; status: completed.
02
Drugs
mufemilast
03
Conditions
psoriasisBehcet's disease (BD)
Beyond the preview
Go deeper on NCT05468645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468645.